https://retacompare.com/news/glp-1-agonists-show-potential-in-obstructive-sleep-apnea-management 2026-10-17T21:45:52.000Z RetatrutideCompare en 2026-10-17T21:45:52.000Z GLP-1 Agonists Show Potential in Obstructive Sleep Apnea Management Clinical Trials, Retatrutide https://retacompare.com/news/fda-raises-concerns-over-unapproved-glp-1-drugs-for-weight-loss 2026-10-17T13:33:47.000Z RetatrutideCompare en 2026-10-17T13:33:47.000Z FDA Raises Concerns Over Unapproved GLP-1 Drugs for Weight Loss Market News, Retatrutide https://retacompare.com/news/retatrutide-developments-future-outlook-on-weight-loss-drug-by-2026 2026-10-17T11:25:12.000Z RetatrutideCompare en 2026-10-17T11:25:12.000Z Retatrutide Developments: Future Outlook on Weight Loss Drug by 2026 Market News, Retatrutide https://retacompare.com/news/retatrutide-shows-cardiovascular-biomarker-benefits-in-obesity-study 2026-10-17T10:51:04.886Z RetatrutideCompare en 2026-10-17T10:51:04.886Z Retatrutide Shows Cardiovascular Biomarker Benefits in Obesity Study Clinical Trials, Retatrutide https://retacompare.com/news/pharmacy-students-evaluate-glp-1-agonist-side-effects-in-obesity-treatment 2026-10-17T04:51:35.686Z RetatrutideCompare en 2026-10-17T04:51:35.686Z Pharmacy Students Evaluate GLP-1 Agonist Side Effects in Obesity Treatment Patient Experiences, Retatrutide https://retacompare.com/news/retatrutide-s-potential-fda-approval-for-weight-loss-by-2026 2026-10-17T02:59:42.000Z RetatrutideCompare en 2026-10-17T02:59:42.000Z Retatrutide's Potential FDA Approval for Weight Loss by 2026 Market News, Retatrutide https://retacompare.com/news/deaths-linked-to-bootleg-versions-of-experimental-weight-loss-drug-reported 2026-10-16T20:47:00.000Z RetatrutideCompare en 2026-10-16T20:47:00.000Z Deaths Linked to Bootleg Versions of Experimental Weight Loss Drug Reported Weight Loss, Retatrutide https://retacompare.com/news/reddit-insights-on-unapproved-glp-1-agonist-surprises-researchers 2026-10-16T16:06:05.000Z RetatrutideCompare en 2026-10-16T16:06:05.000Z Reddit Insights on Unapproved GLP-1 Agonist Surprises Researchers Patient Experiences, Retatrutide https://retacompare.com/news/ema-reviews-new-oral-glp-1-drug-for-diabetes-and-weight-management 2026-10-16T10:00:00.000Z RetatrutideCompare en 2026-10-16T10:00:00.000Z EMA Reviews New Oral GLP-1 Drug for Diabetes and Weight Management Market News, Retatrutide https://retacompare.com/news/glp-1-agonists-exploring-links-to-cancer-risk-and-prevention 2026-10-16T07:54:31.000Z RetatrutideCompare en 2026-10-16T07:54:31.000Z GLP-1 Agonists: Exploring Links to Cancer Risk and Prevention Clinical Trials, Retatrutide https://retacompare.com/news/glp-1-agonists-and-neuroinflammation-potential-in-schizophrenia-treatment 2026-10-16T00:00:00.000Z RetatrutideCompare en 2026-10-16T00:00:00.000Z GLP-1 Agonists and Neuroinflammation: Potential in Schizophrenia Treatment Clinical Trials, Retatrutide https://retacompare.com/news/impact-of-glp-1-agonists-on-heart-outcomes-post-aortic-valve-replacement 2026-10-16T00:00:00.000Z RetatrutideCompare en 2026-10-16T00:00:00.000Z Impact of GLP-1 Agonists on Heart Outcomes Post-Aortic Valve Replacement Clinical Trials, Retatrutide https://retacompare.com/news/comparative-hormonal-responses-post-gdm-in-south-asian-vs-nordic-women 2026-10-16T00:00:00.000Z RetatrutideCompare en 2026-10-16T00:00:00.000Z Comparative Hormonal Responses Post-GDM in South Asian vs Nordic Women Clinical Trials, Retatrutide https://retacompare.com/news/digital-delivery-of-glp-1-therapy-in-women-explored 2026-10-16T00:00:00.000Z RetatrutideCompare en 2026-10-16T00:00:00.000Z Digital Delivery of GLP-1 Therapy in Women Explored Patient Experiences, Retatrutide